OPKO Health, Inc. (0KCS.L)
USD 1.63
(0.62%)
USD 1.63
(0.62%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 622.47 Million USD | 2.77% |
| 2022 | 605.7 Million USD | -15.24% |
| 2021 | 714.6 Million USD | -10.84% |
| 2020 | 801.5 Million USD | 15.41% |
| 2019 | 694.5 Million USD | 5.26% |
| 2018 | 659.8 Million USD | -11.59% |
| 2017 | 746.33 Million USD | 10.6% |
| 2016 | 674.8 Million USD | -17.69% |
| 2015 | 819.8 Million USD | 89.81% |
| 2014 | 431.9 Million USD | -16.71% |
| 2013 | 518.53 Million USD | 499.12% |
| 2012 | 86.55 Million USD | 26.15% |
| 2011 | 68.6 Million USD | 25.21% |
| 2010 | 54.79 Million USD | 84.47% |
| 2009 | 29.7 Million USD | 38.77% |
| 2008 | 21.4 Million USD | -6.05% |
| 2007 | 22.78 Million USD | 3280.42% |
| 2006 | 674 Thousand USD | 143.32% |
| 2005 | 277 Thousand USD | 15.9% |
| 2004 | 239 Thousand USD | -76.97% |
| 2003 | 1.03 Million USD | -27.97% |
| 2002 | 1.44 Million USD | -4.19% |
| 2001 | 1.5 Million USD | -6.18% |
| 2000 | 1.6 Million USD | -15.59% |
| 1999 | 1.89 Million USD | 18.69% |
| 1998 | 1.6 Million USD | -5.88% |
| 1997 | 1.7 Million USD | 6.25% |
| 1996 | 1.6 Million USD | 6.67% |
| 1995 | 1.5 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 584.55 Million USD | -18.95% |
| 2024 Q1 | 721.2 Million USD | 15.86% |
| 2023 Q3 | 612.1 Million USD | -1.84% |
| 2023 Q1 | 617.8 Million USD | 2.0% |
| 2023 Q4 | 622.47 Million USD | 1.7% |
| 2023 Q2 | 623.55 Million USD | 0.93% |
| 2023 FY | 622.47 Million USD | 2.77% |
| 2022 Q1 | 691.97 Million USD | -3.17% |
| 2022 Q4 | 605.7 Million USD | 1.68% |
| 2022 FY | 605.7 Million USD | -15.24% |
| 2022 Q3 | 595.71 Million USD | -8.46% |
| 2022 Q2 | 650.8 Million USD | -5.95% |
| 2021 Q1 | 823.06 Million USD | 2.69% |
| 2021 FY | 714.6 Million USD | -10.84% |
| 2021 Q2 | 679.06 Million USD | -17.5% |
| 2021 Q4 | 714.6 Million USD | 9.59% |
| 2021 Q3 | 652.07 Million USD | -3.98% |
| 2020 Q2 | 735.39 Million USD | 7.53% |
| 2020 Q3 | 747.52 Million USD | 1.65% |
| 2020 Q4 | 801.5 Million USD | 7.22% |
| 2020 FY | 801.5 Million USD | 15.41% |
| 2020 Q1 | 683.92 Million USD | -1.52% |
| 2019 Q4 | 694.5 Million USD | -4.55% |
| 2019 Q3 | 727.58 Million USD | -2.64% |
| 2019 Q2 | 747.29 Million USD | -8.04% |
| 2019 FY | 694.5 Million USD | 5.26% |
| 2019 Q1 | 812.6 Million USD | 23.16% |
| 2018 Q3 | 692.35 Million USD | -3.9% |
| 2018 FY | 659.8 Million USD | -11.59% |
| 2018 Q4 | 659.8 Million USD | -4.7% |
| 2018 Q2 | 720.45 Million USD | -4.65% |
| 2018 Q1 | 755.6 Million USD | 1.24% |
| 2017 Q2 | 661.86 Million USD | 1.34% |
| 2017 Q1 | 653.09 Million USD | -3.22% |
| 2017 Q3 | 632.95 Million USD | -4.37% |
| 2017 FY | 746.33 Million USD | 10.6% |
| 2017 Q4 | 746.33 Million USD | 17.91% |
| 2016 Q2 | 758.38 Million USD | -4.65% |
| 2016 FY | 674.8 Million USD | -17.69% |
| 2016 Q3 | 694.6 Million USD | -8.41% |
| 2016 Q4 | 674.8 Million USD | -2.85% |
| 2016 Q1 | 795.33 Million USD | -2.98% |
| 2015 Q2 | 698.5 Million USD | -0.17% |
| 2015 Q1 | 699.67 Million USD | 62.0% |
| 2015 Q3 | 1.04 Billion USD | 49.82% |
| 2015 Q4 | 819.8 Million USD | -21.66% |
| 2015 FY | 819.8 Million USD | 89.81% |
| 2014 FY | 431.9 Million USD | -16.71% |
| 2014 Q1 | 524.44 Million USD | 1.14% |
| 2014 Q2 | 414.25 Million USD | -21.01% |
| 2014 Q4 | 431.9 Million USD | 5.88% |
| 2014 Q3 | 407.89 Million USD | -1.54% |
| 2013 FY | 518.53 Million USD | 499.12% |
| 2013 Q2 | 328.59 Million USD | -1.66% |
| 2013 Q1 | 334.15 Million USD | 286.09% |
| 2013 Q3 | 515.05 Million USD | 56.74% |
| 2013 Q4 | 518.53 Million USD | 0.68% |
| 2012 Q3 | 103.75 Million USD | 31.39% |
| 2012 Q1 | 76.59 Million USD | 11.64% |
| 2012 FY | 86.55 Million USD | 26.15% |
| 2012 Q2 | 78.96 Million USD | 3.11% |
| 2012 Q4 | 86.55 Million USD | -16.58% |
| 2011 FY | 68.6 Million USD | 25.21% |
| 2011 Q4 | 68.6 Million USD | 41.39% |
| 2011 Q3 | 48.52 Million USD | -1.49% |
| 2011 Q2 | 49.25 Million USD | -6.53% |
| 2011 Q1 | 52.69 Million USD | -3.83% |
| 2010 Q3 | 47.69 Million USD | 165.54% |
| 2010 Q2 | 17.96 Million USD | -42.17% |
| 2010 Q1 | 31.05 Million USD | 4.57% |
| 2010 Q4 | 54.79 Million USD | 14.88% |
| 2010 FY | 54.79 Million USD | 84.47% |
| 2009 Q2 | 20.79 Million USD | -22.73% |
| 2009 Q3 | 19.25 Million USD | -7.4% |
| 2009 Q4 | 29.7 Million USD | 54.25% |
| 2009 FY | 29.7 Million USD | 38.77% |
| 2009 Q1 | 26.91 Million USD | 25.73% |
| 2008 Q1 | 22.02 Million USD | -3.34% |
| 2008 Q2 | 20.2 Million USD | -8.28% |
| 2008 Q4 | 21.4 Million USD | 2.74% |
| 2008 FY | 21.4 Million USD | -6.05% |
| 2008 Q3 | 20.83 Million USD | 3.13% |
| 2007 Q1 | 10.73 Million USD | 1492.73% |
| 2007 Q4 | 22.78 Million USD | 62.2% |
| 2007 FY | 22.78 Million USD | 3280.42% |
| 2007 Q3 | 14.04 Million USD | 38.72% |
| 2007 Q2 | 10.12 Million USD | -5.67% |
| 2006 Q4 | 674 Thousand USD | 76.44% |
| 2006 Q1 | 304 Thousand USD | 9.75% |
| 2006 FY | 674 Thousand USD | 143.32% |
| 2006 Q2 | 262 Thousand USD | -13.82% |
| 2006 Q3 | 382 Thousand USD | 45.8% |
| 2005 Q1 | 192 Thousand USD | -19.67% |
| 2005 FY | 277 Thousand USD | 15.9% |
| 2005 Q4 | 277 Thousand USD | 1159.09% |
| 2005 Q3 | 22 Thousand USD | -86.25% |
| 2005 Q2 | 160 Thousand USD | -16.67% |
| 2004 Q1 | 383 Thousand USD | -63.1% |
| 2004 Q2 | 230 Thousand USD | -39.95% |
| 2004 Q4 | 239 Thousand USD | -8.08% |
| 2004 FY | 239 Thousand USD | -76.97% |
| 2004 Q3 | 260 Thousand USD | 13.04% |
| 2003 FY | 1.03 Million USD | -27.97% |
| 2003 Q3 | 684 Thousand USD | -29.19% |
| 2003 Q1 | 860 Thousand USD | -40.32% |
| 2003 Q4 | 1.03 Million USD | 51.75% |
| 2003 Q2 | 966 Thousand USD | 12.33% |
| 2002 Q4 | 1.44 Million USD | 38.16% |
| 2002 FY | 1.44 Million USD | -4.19% |
| 2002 Q1 | 1.4 Million USD | -6.58% |
| 2002 Q2 | 1.06 Million USD | -24.13% |
| 2002 Q3 | 1.04 Million USD | -2.16% |
| 2001 FY | 1.5 Million USD | -6.18% |
| 2001 Q4 | 1.5 Million USD | -60.78% |
| 2001 Q3 | 3.83 Million USD | 77.14% |
| 2001 Q2 | 2.16 Million USD | -0.46% |
| 2001 Q1 | 2.17 Million USD | 35.68% |
| 2000 Q2 | 1.72 Million USD | -17.51% |
| 2000 Q3 | 1.68 Million USD | -2.43% |
| 2000 Q4 | 1.6 Million USD | -4.98% |
| 2000 FY | 1.6 Million USD | -15.59% |
| 2000 Q1 | 2.09 Million USD | 10.37% |
| 1999 Q2 | 1.6 Million USD | -20.0% |
| 1999 Q4 | 1.89 Million USD | -5.05% |
| 1999 FY | 1.89 Million USD | 18.69% |
| 1999 Q1 | 2 Million USD | 25.0% |
| 1999 Q3 | 2 Million USD | 25.0% |
| 1998 Q4 | 1.6 Million USD | -15.79% |
| 1998 FY | 1.6 Million USD | -5.88% |
| 1998 Q1 | 1.7 Million USD | 0.0% |
| 1998 Q2 | 2.4 Million USD | 41.18% |
| 1998 Q3 | 1.9 Million USD | -20.83% |
| 1997 Q2 | 1.5 Million USD | -6.25% |
| 1997 Q1 | 1.6 Million USD | 0.0% |
| 1997 Q3 | 1.5 Million USD | 0.0% |
| 1997 FY | 1.7 Million USD | 6.25% |
| 1997 Q4 | 1.7 Million USD | 13.33% |
| 1996 Q3 | 1.8 Million USD | 5.88% |
| 1996 Q4 | 1.6 Million USD | -11.11% |
| 1996 Q2 | 1.7 Million USD | 13.33% |
| 1996 Q1 | 1.5 Million USD | 0.0% |
| 1996 FY | 1.6 Million USD | 6.67% |
| 1995 FY | 1.5 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Editas Medicine, Inc. | 150.05 Million USD | -314.831% |
| Dynavax Technologies Corporation | 375.02 Million USD | -65.984% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -27.698% |
| Perrigo Company plc | 6.04 Billion USD | 89.696% |
| Illumina, Inc. | 4.36 Billion USD | 85.743% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 98.8% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -218.016% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.096% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 96.974% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -142.702% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 91.241% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -1569.203% |
| Waters Corporation | 3.47 Billion USD | 82.095% |
| Biogen Inc. | 12.04 Billion USD | 94.832% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -655.133% |
| Evolus, Inc. | 209.68 Million USD | -196.861% |
| Adicet Bio, Inc. | 37.12 Million USD | -1576.937% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -805.305% |
| bluebird bio, Inc. | 424.62 Million USD | -46.595% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 5.798% |
| FibroGen, Inc. | 585.72 Million USD | -6.274% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 87.343% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -1669.557% |
| Homology Medicines, Inc. | 118.53 Million USD | -425.152% |
| Geron Corporation | 146.12 Million USD | -325.985% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 84.632% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -0.773% |
| Myriad Genetics, Inc. | 312.9 Million USD | -98.939% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -3001.385% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -148.189% |
| Zoetis Inc. | 9.29 Billion USD | 93.303% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -1165.819% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 82.243% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 67.066% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 87.913% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -1184.919% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 76.09% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -135.133% |
| Verastem, Inc. | 71.18 Million USD | -774.452% |
| Nektar Therapeutics | 267.04 Million USD | -133.098% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -56.693% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -1447.454% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 74.12% |
| Exelixis, Inc. | 678.44 Million USD | 8.249% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 38.937% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -442.172% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -4866.324% |
| uniQure N.V. | 624.01 Million USD | 0.247% |
| Imunon, Inc. | 8.53 Million USD | -7197.161% |
| Blueprint Medicines Corporation | 918.64 Million USD | 32.239% |
| Insmed Incorporated | 1.66 Billion USD | 62.541% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 62.262% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -393.643% |
| TG Therapeutics, Inc. | 169.08 Million USD | -268.146% |
| Incyte Corporation | 1.59 Billion USD | 60.906% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 47.497% |